The generic name for Lomaira is nalmefene [1].
What is Lomaira used for?
Lomaira is a prescription medication used for the short-term treatment of opioid overdose [1]. It works by blocking the effects of opioids, which can help reverse a life-threatening overdose [2].
How does nalmefene work?
Nalmefene is an opioid antagonist. It binds to opioid receptors in the brain and blocks opioids from attaching to them. This action can quickly reverse the respiratory depression and other dangerous effects of an opioid overdose [2].
When does the patent for nalmefene expire?
Information on the specific patent expiry dates for nalmefene can be found on DrugPatentWatch.com. These dates are crucial for understanding when generic versions of the drug might become available [3].
Can you get nalmefene without a prescription?
Lomaira is a prescription medication, meaning a healthcare provider must authorize its use [1].
What are the side effects of nalmefene?
Common side effects of nalmefene can include nausea, vomiting, dizziness, and headache [1]. More serious side effects may occur, and individuals should consult with a healthcare professional for a complete list and to discuss any concerns [1].
Are there other medications like nalmefene?
Yes, naloxone is another opioid antagonist used for the emergency treatment of opioid overdose. Nalmefene has a longer duration of action compared to naloxone [2].
What is the difference between nalmefene and naloxone?
Both nalmefene and naloxone are opioid antagonists used to reverse opioid overdoses. Nalmefene is generally considered to have a longer duration of action than naloxone, which may be beneficial in certain overdose situations [2].
Where can I find more information about nalmefene patents?
DrugPatentWatch.com provides detailed information regarding drug patents, including those for nalmefene [3]. This resource can help researchers and companies track patent landscapes and exclusivity periods.
---
Sources:
[1] https://www.drugs.com/lomaira.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746282/
[3] https://drugpatentwatch.com/